in

ADAMIS PHARMACEUTICL (ADMP) – Immunology Journal Publishes Data For Adamis’ COVID-19 Candidate

ADAMIS PHARMACEUTICL (ADMP) - Immunology Journal Publishes Data For Adamis' COVID-19 Candidate

  • Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced Tempol data publication in the peer-reviewed journal Clinical Immunology.
  • Tempol is a novel antioxidant that inhibits both activated T cell and APC (Antigen Presenting Cell) derived cytokines in-vitro from COVID-19 patients.
  • The studies conducted at the Human Immune Monitoring Center at Stanford University investigated the effects of Tempol on immune cells from COVID-19 patients. 
  • The authors conclude, “Preincubation of immune cells with Tempol resulted in a significant (P<0.05) decrease in multiple T cell and APC-derived cytokines from both cells of COVID-19 and uninfected donors. 
  • Dr. Holden Maecker, Director of the Human Monitoring Center at Stanford University, commented: “These results suggest that Tempol has strong, broad in-vitro anti-cytokine activity.
  • In animal models, Tempol has been shown to decrease proinflammatory cytokines (cytokine storm) and lung inflammation. 
  • In addition, Tempol works as an antioxidant and has demonstrated decreasing harmful reactive oxygen species and platelet aggregation.
  • Related: NIH Sees Promise in Tempol for COVID-19.
  • Price Action: ADMP shares are up 0.15% at $1.09 during the market session on the last check Tuesday.